Skip to main content
SpringerLink
Log in

Management of the post chemotherapy subcentimeter residual mass: the case for observation

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Donohue JP, Rowland RG, Kopecky K et al (1987) Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 137(6):1176–1179

    PubMed  CAS  Google Scholar 

  2. Steyerberg EW, Keizer HJ, Fossa SD et al (1995) Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic non-seminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 13(5):1177–1187

    PubMed  CAS  Google Scholar 

  3. Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE (1992) Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 10(4):569–573

    PubMed  CAS  Google Scholar 

  4. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD (2003) Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21(17):3310–3317

    Article  PubMed  Google Scholar 

  5. Toner GC, Panicek DM, Heelan RT et al (1990) Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8(10):1683–1694

    PubMed  CAS  Google Scholar 

  6. Karellas M, Carver BS, Stasi J, Motzer RJ, Bosl GJ, Shienfeld J (2007) Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection for men with CII non-seminomatous germ cell tumors and a radiographically normal retroperitoneum. J Urol 177(4):277 (abstract)

    Google Scholar 

  7. Debono DJ, Heilman DK, Einhorn LH, Donohue JP (1997) Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15(4):1455–1464

    PubMed  CAS  Google Scholar 

  8. Nichols CR, Moore CJ, Cho BL, Hayes-Lattin B, Daneshmand S (2008) Management of chemotherapy-induced remissions in patients with disseminated nonseminomatous germ cell tumors: a review of 98 consecutive cases. J Clin Oncol 26

  9. Dash A, Carver BS, Stasi J et al (2008) The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. Cancer 112(4):800–805

    Article  PubMed  Google Scholar 

  10. Einhorn LH, Williams SD, Loehrer PJ et al (1989) Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 7(3):387–391

    PubMed  CAS  Google Scholar 

  11. Saxman SB, Finch D, Gonin R, Einhorn LH (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 16(2):702–706

    PubMed  CAS  Google Scholar 

  12. Culine S, Kerbrat P, Kramar A et al (2007) Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 18(5):917–924

    Article  PubMed  CAS  Google Scholar 

  13. Hendry WF, Norman AR, Dearnaley DP et al (2002) Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94(6):1668–1676

    Article  PubMed  Google Scholar 

  14. Cullen MH, Stenning SP, Parkinson MC et al (1996) Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14(4):1106–1113

    PubMed  CAS  Google Scholar 

  15. Albers P, Siener R, Krege S et al (2008) Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26(18):2966–2972

    Article  PubMed  CAS  Google Scholar 

  16. Pont J, Albrecht W, Postner G et al (1996) Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14(2):441–448

    PubMed  CAS  Google Scholar 

  17. Foster RS, Baniel J, Leibovitch I et al (1996) Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer. J Urol 155(6):1943–1945

    Article  PubMed  CAS  Google Scholar 

  18. Sheinfeld J, Motzer RJ, Rabbani F, McKiernan J, Bajorin D, Bosl GJ (2003) Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. J Urol 170(4 Pt 1):1159–1162

    Article  PubMed  Google Scholar 

  19. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH (1995) Late relapse of testicular cancer. J Clin Oncol 13(5):1170–1176

    PubMed  CAS  Google Scholar 

  20. Shahidi M, Norman AR, Dearnaley DP, Nicholls J, Horwich A, Huddart RA (2002) Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer 95(3):520–530

    Article  PubMed  Google Scholar 

  21. Borge N, Fossa SD, Ous S, Stenwig AE, Lien HH (1988) Late recurrence of testicular cancer. J Clin Oncol 6(8):1248–1253

    PubMed  CAS  Google Scholar 

  22. Dieckmann KP, Albers P, Classen J et al (2005) Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol 173(3):824–829

    Article  PubMed  Google Scholar 

  23. George DW, Foster RS, Hromas RA et al (2003) Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 21(1):113–122

    Article  PubMed  Google Scholar 

  24. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W (1997) Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8(1):41–47

    Article  PubMed  CAS  Google Scholar 

  25. Ravi R, Oliver RT, Ong J et al (1997) A single-centre observational study of surgery and late malignant events after chemotherapy for germ cell cancer. Br J Urol 80(4):647–652

    PubMed  CAS  Google Scholar 

  26. Terebelo HR, Taylor HG, Brown A et al (1983) Late relapse of testicular cancer. J Clin Oncol 1(9):566–571

    PubMed  CAS  Google Scholar 

  27. Krege S, Beyer J, Souchon R et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 53(3):497–513

    Article  PubMed  Google Scholar 

Download references

Conflict of interest statement

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Indiana University, 535N. Barnhill Drive, Suite 420, Indiana Cancer Pavilion, Indianapolis, IN, 46202, USA

    Stephen D. W. Beck & Richard S. Foster

Authors
  1. Stephen D. W. Beck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard S. Foster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen D. W. Beck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beck, S.D.W., Foster, R.S. Management of the post chemotherapy subcentimeter residual mass: the case for observation. World J Urol 27, 485–488 (2009). https://doi.org/10.1007/s00345-009-0452-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-009-0452-7

Keywords

Search

Navigation